HomeCompareSLRX vs PM

SLRX vs PM: Dividend Comparison 2026

SLRX yields 238.10% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRX wins by $339.55M in total portfolio value
10 years
SLRX
SLRX
● Live price
238.10%
Share price
$0.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$339.60M
Annual income
$185,958,933.65
Full SLRX calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — SLRX vs PM

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX
Annual income on $10K today (after 15% tax)
$20,238.10/yr
After 10yr DRIP, annual income (after tax)
$158,065,093.60/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, SLRX beats the other by $158,062,975.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + PM for your $10,000?

SLRX: 50%PM: 50%
100% PM50/50100% SLRX
Portfolio after 10yr
$169.82M
Annual income
$92,980,712.83/yr
Blended yield
54.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

SLRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-14.5
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys
0
PM buys
0
No recent congressional trades found for SLRX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRXPM
Forward yield238.10%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$339.60M$49.6K
Annual income after 10y$185,958,933.65$2,492.02
Total dividends collected$322.91M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: SLRX vs PM ($10,000, DRIP)

YearSLRX PortfolioSLRX Income/yrPM PortfolioPM Income/yrGap
1← crossover$34,510$23,809.52$11,648$408.29+$22.9KSLRX
2$113,715$76,790.22$13,589$495.90+$100.1KSLRX
3$358,160$236,484.38$15,877$603.21+$342.3KSLRX
4$1,079,339$696,107.48$18,580$734.88+$1.06MSLRX
5$3,115,421$1,960,529.07$21,781$896.75+$3.09MSLRX
6$8,622,197$5,288,696.04$25,578$1,096.12+$8.60MSLRX
7$22,905,117$13,679,366.22$30,092$1,342.17+$22.88MSLRX
8$58,470,750$33,962,275.23$35,470$1,646.46+$58.44MSLRX
9$143,588,724$81,025,021.41$41,892$2,023.58+$143.55MSLRX
10$339,598,869$185,958,933.65$49,578$2,492.02+$339.55MSLRX

SLRX vs PM: Complete Analysis 2026

SLRXStock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this SLRX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHDSLRX vs JEPISLRX vs OSLRX vs KOSLRX vs MAINSLRX vs MOSLRX vs BTISLRX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.